At-Home And Mobile Health Expansion Will Drive Long-Term Opportunity In Virtual Care

Catalysts

About Hydreight Technologies

Hydreight Technologies operates a nationwide, multi-vertical digital health platform that powers mobile, bricks-and-mortar and direct-to-consumer medical services across all 50 U.S. states.

What are the underlying business or industry changes driving this perspective?

• The rapid shift toward virtual, at-home and mobile health care, including weight loss and peptide-based therapies, aligns directly with Hydreight’s 50 state compliant infrastructure and VSDHOne platform, supporting sustained volume growth and higher recurring revenue.
• Expanding use of personalized, preventative wellness solutions, from GLP-1 medications to emerging Category 2 peptides and at-home diagnostics, should increase available treatments from roughly 45 to potentially 100, lifting customer lifetime value and long-term revenue per patient.
• The scaled pharmacy footprint via Perfect Scripts and broader compounding capacity improves control over drug supply and pricing, creating room for better gross margins and more resilient earnings as order volumes climb toward the millions per year.
• New high-volume funnels such as ACO physician networks, unions and independent pharmacy groups leveraging VSDHOne for direct-to-consumer programs can add large blocks of patients at relatively low incremental cost, enhancing operating leverage and net income.
• Lower capital expenditure needs after years of infrastructure build-out, combined with automation, improved onboarding and bundled services, should allow incremental revenue from GLP-1, hormone and peptide orders to convert at higher margin, expanding adjusted EBITDA and net income over the next several years.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Hydreight Technologies's revenue will grow by 118.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from 1.9% today to 19.9% in 3 years time.
• Analysts expect earnings to reach CA$50.4 million (and earnings per share of CA$0.99) by about January 2029, up from CA$453.2 thousand today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 11.7x on those 2029 earnings, down from 531.1x today. This future PE is lower than the current PE for the CA Healthcare Services industry at 372.1x.
• Analysts expect the number of shares outstanding to grow by 5.49% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.77%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Hydreight’s rapid growth expectations depend heavily on the still emerging direct-to-consumer virtual care model. If regulatory sentiment shifts or payers and boards become more restrictive on at-home, self-administered treatments, this could slow patient adoption and materially reduce long-term revenue growth.
• Roughly 40% of order volume is currently tied to GLP 1 therapies and the broader peptide space. If FDA enforcement, big pharma pricing moves, or shifts in compounding rules curb demand or margins for these treatments, it would pressure average order values, compress gross margins, and weaken earnings expansion.
• The plan to scale VSDHOne to millions of annual orders assumes smooth migration of existing high-volume partners and rapid onboarding of new licensees. Operational bottlenecks in migration, technology, or partner marketing effectiveness could slow order ramp, leaving revenue below forecasts and limiting operating leverage on net income.
• The strategy leans on long-term expansion of Category 2 peptides and new at-home diagnostics. If legislation does not evolve as anticipated or key peptides remain constrained, the expected increase in available treatments and customer lifetime value may not materialize, capping upside for revenue per patient and future profit margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CA$8.5 for Hydreight Technologies based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CA$253.8 million, earnings will come to CA$50.4 million, and it would be trading on a PE ratio of 11.7x, assuming you use a discount rate of 7.8%.
  
• Given the current share price of CA$4.85, the analyst price target of CA$8.5 is 42.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.